Get the Stockscreener App
2.89
0.35%
0.01
Dare Bioscience Inc stock is traded at $2.89, with a volume of 15,116.
It is up +0.35% in the last 24 hours and down -0.69% over the past month.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
See More
Previous Close:
$2.88
Open:
$2.91
24h Volume:
15,116
Relative Volume:
0.77
Market Cap:
$25.58M
Revenue:
-
Net Income/Loss:
$-30.16M
P/E Ratio:
-8.50
EPS:
-0.34
Net Cash Flow:
$-39.49M
1W Performance:
-0.69%
1M Performance:
-0.69%
6M Performance:
-9.97%
1Y Performance:
+564.67%
1-Day Range:
$2.8824
$2.92
1-Week Range:
$2.88
$2.9406
52-Week Range:
$0.326
$4.60
Dare Bioscience Inc Stock (DARE) Company Profile
Name
Dare Bioscience Inc
Sector
Industry
Phone
858-926-7655
Address
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
2.89 | 25.75M | 0 | -30.16M | -39.49M | -0.34 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Dare Bioscience Inc Stock (DARE) Latest News
Q2 EPS Estimate for Daré Bioscience Increased by Analyst - Defense World
Daré outlines expanded dual path strategy targeting $4.5B hormone therapy market while accelerating commercialization in Q4 2025 - MSN
Daré Bioscience’s Earnings Call: Strategic Moves Amid Challenges - TipRanks
Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2025 Earnings Call Transcript - Insider Monkey
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates - MSN
Dare Bioscience Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Dare Bioscience (DARE) Expands Strategy to Enhance Value for Sta - GuruFocus
Dare Bioscience Inc (DARE) Q1 2025 Earnings Call Highlights: Strategic Expansions and Cost ... - Yahoo Finance
Daré Bioscience Expands Women’s Health Portfolio - TipRanks
Earnings call transcript: Dare Bioscience Q1 2025 unveils new products and cost cuts By Investing.com - Investing.com South Africa
Earnings call transcript: Dare Bioscience Q1 2025 unveils new products and cost cuts - Investing.com India
Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update - The Manila Times
Daré Bioscience Q1 2025 Financial Results and Company Update - TradingView
Daré Bioscience Unveils Major Commercial Push: 4 Women's Health Products Coming to $4.5B Market by 2026 - Stock Titan
Daré Bioscience (DARE) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Daré Bioscience, Inc. (NASDAQ:DARE) Shares Purchased by Renaissance Technologies LLC - Defense World
Daré Bioscience to Host First Quarter 2025 Financial - GlobeNewswire
Daré Bioscience Q1 Earnings: Women's Health Innovator to Share Latest Financial Results May 13 - Stock Titan
Geode Capital Management LLC Purchases 3,593 Shares of Daré Bioscience, Inc. (NASDAQ:DARE) - Defense World
Daré Bioscience targets Q4 2025 for Sildenafil Cream launch via 503B compounding - MSN
Daré Bioscience to Present at the Fierce Pharma Engage - GlobeNewswire
Daré CEO Unveils Game-Changing Women's Health Pipeline: Sildenafil Cream Launch Timeline Confirmed - Stock Titan
Daré Bioscience (NASDAQ:DARE) Share Price Crosses Below 200-Day Moving Average – Here’s What Happened - Defense World
Dare Bioscience granted extension by Nasdaq to regain compliance - Investing.com Australia
Daré Bioscience to Present at the Jones Healthcare and - GlobeNewswire
Daré's Game-Changing Strategy: Sildenafil Cream Heads to Prescription Market Earlier Than Expected - Stock Titan
Daré Bioscience Q1 EPS Estimate Increased by HC Wainwright - Defense World
Q1 EPS Estimate for Daré Bioscience Decreased by Analyst - Defense World
HC Wainwright Forecasts Daré Bioscience FY2029 Earnings - Defense World
Short Interest in Daré Bioscience, Inc. (NASDAQ:DARE) Rises By 22.2% - Defense World
Daré Bioscience (NASDAQ:DARE) Receives Buy Rating from HC Wainwright - Defense World
Daré Bioscience Earnings Call: Strategic Progress Amid Challenges - TipRanks
Daré Bioscience (DARE) Anticipates Revenue Boost from Sildenafil Cream in 2025 - GuruFocus
Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2024 Earnings Call Transcript - Insider Monkey
Dare Bioscience Inc (DARE) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial ... - Yahoo Home
Earnings call transcript: Dare Bioscience Q4 2024 focuses on women’s health innovations - Investing.com
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Dare Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Daré Bioscience Reports Full Year 2024 Financial Results - MarketScreener
DARE BIOSCIENCE Earnings Results: $DARE Reports Quarterly Earnings - Nasdaq
Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update - TradingView
Daré Bioscience Reveals New Revenue Strategy: Sildenafil Cream Launch Coming Q4 2025 - Stock Titan
Daré Bioscience (NASDAQ:DARE) Stock Price Passes Below 200-Day Moving Average – Time to Sell? - Defense World
Upcoming: Daré Bioscience Full Year Results Reveal Women's Health Innovation Progress - StockTitan
Daré Bioscience to Host Full Year 2024 Financial Results - GlobeNewswire
Daré Bioscience (DARE) Projected to Post Quarterly Earnings on Thursday - Defense World
Daré Bioscience (NASDAQ:DARE) Shares Cross Below 200-Day Moving Average – Should You Sell? - Defense World
Dare Bioscience, Inc. to Host Earnings Call - ACCESS Newswire
Daré Bioscience and Theramex Announce Co-Development and - GlobeNewswire
Dare Bioscience and Theramex Announce Co-Development and Licensing Agreement for A Potential Biodegradable Long-Acting Contraceptive Implant - Marketscreener.com
Daré, Theramex partner on biodegradable contraceptive implant - Investing.com
Dare Bioscience Inc Stock (DARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):